Table 2 Bivariate analysis of risk factors related to inflammation and hepatic fibrosis classified according to the METAVIR scale
FACTORS | Degree of hepatic inflammation | Degree of liver fibrosis | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
A0-A1 | A2-A3 | P | Odds ratio | CI 95% | F0-F1 | F2 | F3-F4 | P | Odds ratio | CI 95% | |
GENDER | n (%) | n (%) | n (%) | n (%) | n (%) | ||||||
Male | 43 (62.32) | 19 (55.88) | 0.67♠ | 29 (59.18) | 16 (61.54) | 17 (60.71) | 0.98Ω | ||||
Female | 26 (37.68) | 15 (44.12) | 20 (40.82) | 10 (38.46) | 11 (39.29) | ||||||
VL (log10) (median) | 5.4109 | 5.3664 | 0.65♦ | 4.4402 | 5.6433 | 5.6503 | < 0.05Ψ | 1.97* | 0.34–0.75 | ||
ALT | |||||||||||
≤ 34 UI/L | 26 (40.00) | 1 (03.23) | < 0.01♠ | 20.00# | 1.57–155.87 | 20 (42.55) | 4 (15.38) | 3 (13.04) | 0.01■ | 9.74# | 1.16–81.69 |
> 34 UI/L | 39 (60.00) | 30 (96.77) | 27 (57.45) | 22 (84.66) | 20 (86.96) | ||||||
AST | |||||||||||
≤ 55 UI/L | 44 (67.69) | 10 (31.25) | < 0.01♠ | 4.61# | 1.85–11.46 | 30 (62.50) | 15 (57.69) | 9 (30.13) | 0.17■ | ||
> 55 UI/L | 21 (32.31) | 22 (68.75) | 18 (37.50) | 11 (42.31) | 14 (60.87) | ||||||
GGT | |||||||||||
≤ 64 UI/L (♂) ≤36 UI/L (♀) | 41 (67.21) | 7 (21.88) | < 0.01♠ | 7.32# | 2.71–19.78 | 26 (57.78) | 12 (50.00) | 10 (41.67) | 0.44■ | ||
> 64 UI/L (♂) > 36 UI/L (♀) | 20 (32.79) | 25 (78.12) | 19 (42.22) | 12 (50.00) | 14 (58.33) | ||||||
Ethylism | |||||||||||
No | 36 (72.00) | 14 (28.00) | 0.65♠ | 26 (52.00) | 13 (26.00) | 11 (22.00) | 0.83■ | ||||
Yes | 33 (66.00) | 17 (34.00) | 23 (46.00) | 14 (28.00) | 13 (26.00) | ||||||
Comorbidities | |||||||||||
No | 33 (78.57) | 9 (21.43) | 0.04♠ | 2.55# | 1.04–6.24 | 29 (69.05) | 4 (09.52) | 9 (21.43) | < 0.01■ | 1.63* | – |
Yes | 36 (59.02) | 25 (40.98) | 20 (32.79) | 23 (37.70) | 18 (29.51) | ||||||